Collaboration enables direct integration of DataHow's digital solutions with Genedata's platform, accelerating the development of next-generation biotherapeutics
BASEL and ZURICH, Switzerland, Sept. 12, 2022 /PRNewswire-PRWeb/ –Genedata and DataHow, both leading innovators for the digital transformation of biopharma R&D, entered a strategic partnership to integrate their platforms to further streamline bioprocess development and manufacturing workflows. The combined solution will directly integrate DataHow's Digital Twin products, including DataHowLab and SpectraHow, with the Genedata Biopharma Platform so that process development and manufacturing data can be seamlessly exchanged and interpreted. Having experimental data and modelling data available together will streamline digitalization across biopharma process development and manufacturing. This will enable digital tracking of data for every molecule, sample, and process for more efficient process development and integrate state-of-the-art modelling capabilities to better understand and optimize critical attributes of the biopharmaceutical manufacturing process.
DataHow's platform provides high-performance bioprocess data analysis and predictive modelling tools based on a user-friendly workflow with customized data visualization techniques, hybrid modelling for process understanding and design, and machine-learning to enable self-learning capabilities and knowledge transfer across molecules and scales. Genedata Bioprocess® is a fully integrated biopharma R&D workflow platform, which integrates processes and connects people, data, and laboratory instruments to automate corporate-wide development and manufacturing operations. It supports the entire end-to-end (E2E) process, covering cell line development (CLD), upstream process development (USP), downstream process development (DSP), formulation development (FD), process analytical support, and analytical development (AD). The integration of the platforms results in synergies that further drive harmonization and automation along the full process. Additionally, as part of the collaboration, DataHow and Genedata will expand the integrated platform to other innovation areas in process development and manufacturing, including hybrid model-supported process monitoring and control with Raman Spectroscopy and E2E applications of Digital Twins.
"The development of innovative biotherapeutics, including cell and gene therapies and next-generation vaccines, is based on extremely complex and data-rich R&D processes," noted Othmar Pfannes, Ph.D., CEO of Genedata. "The Genedata Biopharma Platform enables full automation of experimental workflows due to its flexible data model and open programming interfaces. It also allows emerging technology leaders such as DataHow to integrate their technology platform, minimizing setup and integration work for joint customers and directly creating value out of the generated data. This integration provides the best of both worlds — fully automated high-throughput processes complemented by a comprehensive modelling platform supporting faster and better decision making for process development and manufacturing."
"Full digitalization of production processes is at the heart of DataHow's vision. Digitalization will allow users to perform a large majority of tasks related to manufacturing processes in silico and automated. This includes process predictive monitoring, optimization, scenario and deviation analysis, and quality management," said Alessandro Butté, CEO of DataHow AG. "Both companies share a common vision — providing the biopharma industry with one holistic platform that seamlessly communicates between all involved stakeholders, allowing to manage bioprocess data and knowledge in a comprehensible digital format. Our collaboration with Genedata will streamline the whole biopharma lifecycle from process development to late-stage manufacturing."
About DataHow
DataHow is a software provider focused on accelerating process development, optimizing manufacturing processes, and increasing robustness by using hybrid modeling solutions. Our software and services are tailored to upstream (cell culture, fermentation, seed train, etc.) and downstream (chromatography, ultrafiltration, diafiltration, etc.) biopharma operations providing the user with essential insights for process development, characterization, and scale-up. Our unique Digital Twin technology allows to handle all process units and their interactions, and to transfer knowledge between scales, projects, and product targets. With our approach we want to support the decision process of process experts, scientists, and operators by leveraging in our technology all available process data and knowledge. DataHow was incorporated in 2017 as a spin-off from ETH Zurich and operates with 45 team members across 3 continents.
http://www.datahow.ch
LinkedIn
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
http://www.genedata.com
LinkedIn| Twitter| YouTube
________________________________________
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Media Contact
Allison Kurz, Genedata, +41615118459, pr@genedata.com
SOURCE Genedata
PowerHome Solar, doing business as Pink Energy, has laid off about 1,100 workers in the last two weeks and halted installations in North Carolina, Texas and Georgia as the financial fallout continues from defective equipment provided by Generac.
The long-awaited upgrade to one of crypto's key networks will also be felt in the stock market, from trading platforms to chip makers.
Though retirees are only required to take a certain portion of their retirement savings out as distributions each year, a study from JPMorgan Chase shows that there is likely good reason to take out more. A withdrawal approach based solely on … Continue reading → The post 84% of Retirees Are Making This RMD Mistake appeared first on SmartAsset Blog.
BlackBerry (NYSE: BB) and CrowdStrike (NASDAQ: CRWD) represent two very different ways to invest in the cybersecurity market. BlackBerry reinvented itself as an enterprise-oriented cybersecurity company after retreating from the smartphone market. CrowdStrike has been disrupting traditional cybersecurity companies with its cloud-native Falcon platform.
EV leader Tesla, like the whole automotive industry, is facing a sharp increase in a particular development cost.
Alphabet subsidiary Google is reportedly facing damages claims of up to €25 billion ($25.4 billion) in two upcoming court cases in the U.K and the Netherlands over its digital advertising practices.
The remarks are the latest signal that the group is prepared to backstop the oil market and prevent prices from falling much further, confounding efforts by Western governments to ease the pain of high energy prices.
In this piece, we will take a look at the ten best lithium stocks to buy now. If you want to jump ahead to the top five stocks in this list, then head on over to the 5 Best Lithium Stocks to Buy Now. Just as the internal combustion vehicle is dependent on the crude […]
It's time to be extra picky.
Silicon Valley startup SiFive Inc on Tuesday launched three new products aimed at the automotive market, which is emerging as one of the hottest areas for chip makers with electric and self-driving cars expected to boost the number of chips needed. The new chip designs launched are the E6-A series for digital control applications like steering, S7-A for so-called "safety islands" that act as a failsafe for other critical applications, and X280-A to manage data from image sensors and do machine learning work, including for autonomous driving. Before SiFive, Little helped build Qualcomm’s automotive business, and said both Qualcomm Inc and Nvidia Corp could be great customers and partners for SiFive.
Today's video focuses on Taiwan Semiconductor Manufacturing (NYSE: TSM) and its recently reported monthly revenue report for August 2022. While specific industries in the semiconductor market seem to be slowing down in growth, the manufacturing market continues to accelerate.
Ahead of a potential strike this week, analysts at Bank of America upgraded the three largest publicly-traded railroad operators as trends for the industry improve.
(Bloomberg) — It’s that time of year again when your iPhone gets an upgrade, giving you a slew of new features to tinker with. Apple’s iOS 16 is available for download now for owners of the iPhone 8 and onwards. Apple says the new operating system offers “all-new personalization features, deeper intelligence, and more seamless ways to communicate and share.”Here are just some of the new features you can expect to see when you upgrade: Lock ScreenThis time round, the company is making a big deal
BMO Capital Markets analyst Keith Bachman downgraded Adobe Systems Inc. shares to market perform from outperform Tuesday, though he noted that his ratings change reflected the results of a broader survey on interest in the company's Creative Cloud suite of software rather than specific concerns about the upcoming quarterly results Adobe is due to report Thursday. "In short, respondents across the board expressed a greater willingness to move away from Adobe Creative Cloud in our August survey co
Congressional Democrats want to slam shut a tax loophole known as the "backdoor" Roth IRA. In one of several proposed changes that target the retirement accounts of wealthy Americans, Democrats on the House Ways and Means Committee want to prohibit people … Continue reading → The post Democrats Want to End This Lucrative Retirement Account Loophole appeared first on SmartAsset Blog.
Goldman Sachs gets rid of its free coffee as it restarts its five-day, in-office workweek.
Alphabet's (GOOGL) Google shows images of the new wired Nest Doorbell, which it will launch on Oct 6.
Energy stocks are the uncontested winners in the S&P 500 this year (^GSPC). They continue to "look extremely attractive," says one fund manager.
Shares of Apple (NASDAQ: AAPL) climbed higher on Monday, adding as much as 3.5%. Wedbush's Daniel Ives has been keeping a close eye on Apple's website and notes that delivery times have quickly been pushed out to mid-October for the more expensive iPhone 14 Pro models, while the remaining preorders will take at least three weeks to process and wait times are quickly getting longer, according to The Fly. Ives noted that not only are iPhone 14 orders tracking ahead of his expectations, but consumers are ordering more Pro and Pro Max models, which will drive up the average selling price (ASP) for Apple.
(Bloomberg) — Oracle Corp.’s quarterly sales jumped 18%, buoyed by the software maker’s transition to cloud computing and the acquisition of health records provider Cerner.Sales were $11.4 billion in the fiscal first quarter, meeting analysts’ average estimate, according to data compiled by Bloomberg. Profit, excluding some items, was $1.03 a share. Oracle said currency fluctuations reduced the earnings by 8 cents a share. Analysts projected $1.06 a share. Cloud revenue — the highly watched se